GRM is under clinical development by Grunenthal and currently in Phase I for Inflammation. According to GlobalData, Phase I drugs for Inflammation have a 44% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how GRM’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

GRM overview

The drug candidate is under development for the treatment of inflammation, rheumatoid arthritis. It is administered through oral route. The drug candidate acts by targeting glucocorticoid receptor (GR).

Grunenthal overview

Grunenthal is a research-oriented pharmaceutical company that researches, develops and markets products for the treatment of pain management and related diseases. Its portfolio includes a wide range of medicinal products for chronic and acute pain, nociceptive and neuropathic pain. The company’s products portfolio include Tramal used for the treatment of moderate to severe pain; Transtec used to treat moderate to severe cancer pain; and Vimovo used for the treatment of rheumatoid arthritis, osteoarthritis and ankylosing spondylitis. The company distributes products and operates in Europe, Latin America and the US. Grunenthal is headquartered in Aachen, Nordrhein-Westfalen, Germany.

For a complete picture of GRM’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.